KCT0002985尚未招募未知
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide/dexamethasone-containing regimens
Chonnam National University Hospital Hwasun Hospital0 个研究点目标入组 33 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •(1) Relapsed or refractory multiple myeloma who received pomalidomide and dexamethasone-containing regimen
- •(2) Absolute neutrophil count = 15,000/µL at screening
- •(3) Age = 19 years
- •(4) ECOG PS = 2
- •(5) Subjects must have signed an informed consent document indicating that they understand purpose
- •of and procedures required for the study and are willing to participate in the study.
排除标准
- •(1) Smoldering myeloma
- •(2) Primary or secondary plasma cell leukemia
- •(3) History of radiation therapy within 4 weeks prior to enrolment
- •(4) Patients who have hypersensitivity to pegfilgrastim
- •(5) Presence of abnormal result of baseline test
- •Platelet count < 50,000 cells/µL (50 x 109/L) (when patients do not received a blood transfusion)
- •Serum AST or ALT > 3 X normal range
- •(6) Renal failure with hemodialysis or peritoneal dialysis
- •(7) Presence of Uncontrolled severe infection
- •(8) Pregnant or lactating female
研究者
相似试验
进行中（未招募）
不适用
A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancerEUCTR2006-004857-86-FRCaprion Pharmaceuticals Inc.40
进行中（未招募）
不适用
Study of the clinical activity and safety of vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia carrying the BRAF-V600E mutatioHairy cell leukemia (HCL)carrying the BRAF-V600 mutationMedDRA version: 14.1Level: PTClassification code 10019053Term: Hairy cell leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005487-13-ITIVERSITA' DEGLI STUDI DI PERUGIA
招募中
2 期
A phase 2 multicenter, open-labeled study of efficacy and safety of Deferasirox GPO in thalassemia patients with iron overloadtransfusion dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT) patients who have iron overloadthalassemia, iron overloadTCTR20240601004The Government Pharmaceutical Organization (GPO)160
进行中（未招募）
不适用
An open label multicenter phase 2 study for the initial evaluation of the tolerability of Birch pollen extract in patients suffering from atopic eczema and clinical relevant IgE-mediated sensitization against birch pollen.EUCTR2007-004876-38-DEETI Pharma GmbH
进行中（未招募）
1 期
A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignanciesAdvanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, gastric cancer, melanoma, renal cell cancer, pancreatic cancer, cervical cancer, and triple negative breast cancer (BC)MedDRA version: 21.0Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077738Term: Hepatocellular carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10033609Term: Pancreatic carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10038389Term: Renal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignantEUCTR2018-003172-12-ITKymab Limited412